Immunotherapy treatments approved for stage 4 (IV) or metastatic non-small cell lung cancer (cancer that has spread outside of one lung)
These drugs are approved for patients with advanced non-small cell lung cancer:
FIRST LINE (as your first treatment)
-
Combination Imfinzi (durvalumab, a PD-L1 inhibitor) with Imjudo (tremelimumab, a CTLA-4 inhibitor) – approved with chemotherapy for people with stage 4 (IV) NSCLC without EGFR or ALK mutations.
- Keytruda (pembrolizumab, a PD-1 Inhibitor) – approved for stage 4 (IV) NSCLC patients in combination with chemotherapy. Keytruda is also approved for stage 4 NSCLC patients with >1% PD-L1 without chemotherapy.
- Libtayo (cemiplimab-rwlc, a PD-1 Inhibitor) – approved for stage 4 (IV) NSCLC patients with >50% PD-L1 without chemotherapy.
- Yervoy (ipilimumab, a CTLA-4 Inhibitor) plus Opdivo (nivolumab, a PD-1 Inhibitor) – approved for stage 4 (IV) NSCLC patients with >1% PD-L1 in combination with Opdivo. Yervoy is also approved for stage 4 (IV) NSCLC patients in combination with Opdivo and two cycles of platinum doublet chemotherapy.
LATER LINES OF THERAPY (after another treatment)
- Combination Imfinzi (durvalumab, a PD-L1 inhibitor) with Imjudo (tremelimumab, a CTLA-4 inhibitor) – approved with chemotherapy for people with stage 4 (IV) NSCLC without EGFR or ALK mutations.
- Keytruda (pembrolizumab, a PD-1 Inhibitor) – approved for stage 4 (IV) NSCLC patients in combination with chemotherapy. Keytruda is also approved for stage 4 (IV) NSCLC patients with >1% PD-L1 without chemotherapy.
- Opdivo (nivolumab, a PD-1 Inhibitor) – approved for stage 4 (IV) NSCLC patients who have progressed on platinum doublet chemotherapy.
- Tecentriq (atezolizumab, a PD-L1 Inhibitor) – approved for stage 4 (IV) NSCLC patients in combination with Avastin and platinum doublet chemotherapy. Tecentriq is also approved for stage 4 (IV) NSCLC patients who have progressed on platinum doublet chemotherapy.
Click here for answers to frequently asked questions about immunotherapy for lung cancer.